



GUJARAT TERCE LABORATORIES LIMITED

Date: 10-02-2025

To, BSE Limited Corporate Relation Department Phiroze Jeejeebhoy Towers, Dalal Streets, Mumbai- 400001, Maharashtra, India	Scrip Code: 524314 Security ID: GUJTERC ISIN: INE499G01013
--	---

Dear Sir/Madam,

Sub: Updated Investors Presentation for Quarter ended on December 31, 2024

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith updated Investor Presentation for the quarter ended December 31, 2024. We would like to inform you that the following changes have been made in Investors presentation:

“in lacs instead of in crores that was mentioned in slide number 4 – ‘Profit and Loss Summary’, has been amended.

There is no other change in Investors presentation. Kindly take the same on your records.

Thanking you,
Yours faithfully,

For, Gujarat Terce Laboratories Limited

**Aalap
Prajapati**

Digitally signed by Aalap Prajapati
DN: cn=B, ou=Personal, title=9696,
pseudoyma=133546800989773877On
9432am1955,
2.5.4.20=d6edca32194c21b4ecf796d7a
7200929c6c5728c0eab660b1641290
036f, postalCode=380029, st=Gujarat,
serialNumber=31642664e4ed313558,
1.017696356948b6c1a18d526c9dd
d7047a31b1, cn=Aalap Prajapati
Date: 2025.02.10 13:07:35 +05'30'

Mr. Aalap Prajapati
Managing Director
(DIN: 08088327)
Encl: As attached



GUJARAT TERCE LABORATORIES LIMITED



Q3 FY25 | FINANCIAL RESULTS & BUSINESS UPDATE



SAFE HARBOUR

THIS PRESENTATION CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS CONCERNING OUR FUTURE BUSINESS PROSPECTS AND BUSINESS PROFITABILITY, WHICH ARE SUBJECT TO SEVERAL RISKS AND UNCERTAINTIES & THE ACTUAL RESULTS COULD MATERIALLY DIFFER FROM THOSE IN SUCH FORWARD-LOOKING STATEMENTS. THE RISKS AND UNCERTAINTIES RELATING TO SUCH STATEMENTS INCLUDE BUT ARE NOT LIMITED TO, EARNINGS FLUCTUATIONS, OUR ABILITY TO MANAGE GROWTH, COMPETITION, ECONOMIC GROWTH IN INDIA, ABILITY TO ATTRACT & RETAIN HIGHLY SKILLED PROFESSIONALS, TIME & COST OVERRUNS ON CONTRACTS, GOVERNMENT POLICIES AND ACTIONS RELATED TO INVESTMENTS, REGULATION & POLICIES ETC., INTEREST & OTHER FISCAL POLICIES GENERALLY PREVAILING IN THE ECONOMY. THE COMPANY DOES NOT UNDERTAKE TO MAKE ANY ANNOUNCEMENTS IN CASE ANY OF THESE FORWARD-LOOKING STATEMENTS BECOME INCORRECT IN FUTURE OR UPDATE ANY FORWARD-LOOKING STATEMENTS MADE FROM TIME TO TIME ON BEHALF OF THE COMPANY.

PERFORMANCE HIGHLIGHTS



(INR lacs)

REVENUE		EBIDTA		NET PROFIT		PCPM	
Q3/FY24	Q3/FY25	Q3/FY24	Q3/FY25	Q3/FY24	Q3/FY25	Q3/FY24	Q3/FY25
1302	1268.08	92.69	115.75	67.28	100.8	2.00	2.73
-3% Degrowth		25% INCREASE		50% INCREASE		36.5% INCREASE	

EARNINGS PER SHARE		EBIDTA MARGIN		ROCE	
Q3/FY24	Q3/FY25	Q3/FY24	Q3/FY25	9M FY 24	9M FY 25
0.91	1.36	7.12 %	9.13 %	2 %	21 %
50% INCREASE					



PROFIT & LOSS SUMMARY

(INR lacs)

Particulars	Q3 FY25	Q3 FY24	Change %	9 M FY25	9 M FY24	Change %	2023-24
Revenue	1268.08	1302.02	(3) %	3787.08	3576.76	5.88 %	4797.47
EBITDA	115.75	92.69	25 %	305.09	50.16	508.23 %	158.7
Cash Profit	110.33	76.39	44 %	269.47	(2.66)		61
PBT	97.77	67.28	45 %	242.20	(30)	907 %	54.4
Deferred Taxes	(3.03)	-		0.94	-		30
Reported PAT	100.8	67.28	50 %	241.26	(30)	904 %	24.3
EBITDA Margin	9.13 %	7.12 %		8.06 %	1.40 %		3.3 %
PAT Margin	7.95 %	5.17 %		6.37 %	(0.84)		0.5 %
Cash Profit	8.70 %	5.87 %		7.12 %	(0.07)		1.27 %



MANAGEMENT COMMENTARY

Dear Shareholders,

On behalf of the entire team at Gujarat Terce Laboratories Limited, I am pleased to share our financial performance for Q3 FY25. Our strategic initiatives and operational excellence continue to drive positive momentum, positioning us for sustainable long-term growth.

Financial Highlights (Q3 FY25 vs. Q3 FY24):

- **Revenue:** ₹1,268.08 lacs (down 3% YoY)
- **EBITDA:** ₹115.75 lacs (up 25%)
- **Cash Profit:** ₹110.33 lacs (up 44%)

Key Business Drivers & Strategic Focus

Our robust performance is driven by:

1. Strengthening engagement with key opinion leaders (KOLs) and key business leaders (KBLs) in the healthcare sector
2. Optimizing our brand portfolio to enhance market competitiveness
3. Prioritizing secondary sales growth
4. Maintaining steady demand and effective channel management
5. Improving collection efficiency and optimizing inventory levels

Additionally, we continue investing in **team development, digital transformation, and brand-focused approach**, ensuring our organization remains agile and competitive.

Looking Ahead

We are dedicated to building a **sustainable, high-performing business** that delivers consistent value to our shareholders. By benchmarking ourselves against industry best practices, we are **continuously learning, evolving, and strengthening our market presence**.

I sincerely thank our shareholders, employees, and partners for their continued trust and support. The future holds immense opportunities, and we are confident in our ability to capitalize on them.

We remain committed to building a sustainable, high-performing business that delivers value to our shareholders

Yours sincerely,
Aalap Prajapati
CEO

ABOUT THE COMPANY

Gujarat Terce has over three decades of experience in manufacturing and marketing branded generics to provide the general public with accessible healthcare.


COMPASSION & EXCELLENCE

- We have an extensive basket of 50 Brands (125 products) with a portfolio contributing to 10 therapeutic areas
- Our operations are spread across 13 states in India and cater to 29000+ healthcare professionals, with brands available across a network of 43500+ chemists
- We substantially invest in formulation and development, and research to identify gaps in therapeutic areas and address patients' healthcare needs




Total Area of the Facility

3,375 sq mt




Tablets Manufacturing Capacity

720 Lakhs



Capsules Manufacturing Capacity

185 Lakhs



GUJARAT TERCE

THANK YOU

For more information, contact:

Ms. Ripal Sukhadia
Company Secretary

cs@gujaratterce.com